Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2; * Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×109/L, Platelet count≥100×109/L, Hemoglobin≥80g/L, Serum bilirubin≤24umol/L, Alanine aminotransferase and aspartate aminotransferase ≤ 60×IU/L, Serum creatinine≤110 umol/L; * No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception ; * Be in a condition to receive a surgery/procedure; * No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer; * No previous systemic chemotherapy for treating colon cancer; * No other chemotherapy at the same time; * Expected lifetime longer than three months; * Be willing and able to understand the study and to provide written informed consent. Exclusion Criteria: * End-stage cachexia patients; * Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy; * Metastatic carcinoma; * Moderate or above anemia caused by serious local tumor bleeding; * Incomplete or complete intestinal obstruction; * Known to be allergic to oxaliplatin or capecitabine; * Active hepatitis, severe coagulation disorder patients; * Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures; * Known to have deficient dihydropyrimidine dehydrogenase (DPD)； * Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric history；severe infection; active disseminated intravascular coagulation; * Unable or unwilling to abide by the study plan.